Fluorescent CXCR4 chemokine receptor antagonists: metal activated binding
Open Access
- 4 December 2006
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- No. 4,p. 416-418
Abstract
The copper(II) complex of a novel rhodamine-azamacrocycle conjugate binds to the CXCR4 chemokine receptor and competes effectively against anti-CXCR4 monoclonal antibodies. The copper macrocycle unit adopts a trans-II configuration in the solid state.Keywords
This publication has 27 references indexed in Scilit:
- Therapeutic potential of cytokine and chemokine antagonists in cancer therapyEuropean Journal of Cancer, 2006
- The clinical potential of chemokine receptor antagonistsPharmacology & Therapeutics, 2005
- A two-dimensional chromogenic sensor as well as fluorescence inverter: selective detection of copper(ii) in aqueous mediumNew Journal of Chemistry, 2005
- Does a Reinforced Kinetic Macrocyclic Effect Exist? The Demetallation in Strong Acid of Copper(II) Complexes with Open and Cyclic Tetramines Containing a Piperazine FragmentChemistry – A European Journal, 2004
- Configurations of metallocyclams and relevance to anti-HIV activityJournal of Inorganic Biochemistry, 2004
- Selective Recognition of Configurational Substates of Zinc Cyclam by Carboxylates: Implications for the Design and Mechanism of Action of Anti‐HIV AgentsChemistry – A European Journal, 2003
- Bis-aminals: efficient tools for bis-macrocycle synthesisNew Journal of Chemistry, 2001
- Synthesis and Characterization of Cross-Bridged Cyclams and Pendant-Armed Derivatives and Structural Studies of Their Copper(II) ComplexesJournal of the American Chemical Society, 2000
- WinGXsuite for small-molecule single-crystal crystallographyJournal of Applied Crystallography, 1999
- Flow cytometric assessment of the cellular pharmacokinetics of fluorescent drugsCytometry, 1995